meningococcal disease

meningococcal disease
Name	Meningococcal disease
Caption	Neisseria meningitidis bacteria (colorized SEM), the causative agent.
Field	Infectious disease
Symptoms	Fever, headache, neck stiffness, petechial rash
Complications	Gangrene, hearing loss, brain damage, septic shock
Onset	Rapid
Causes	Neisseria meningitidis
Risks	Complement deficiency, asplenia, smoking, crowding
Diagnosis	CSF analysis, blood culture
Prevention	Vaccination, antibiotic prophylaxis
Treatment	Intravenous antibiotics, supportive care
Medication	Ceftriaxone, penicillin G, ciprofloxacin
Prognosis	~10% mortality
Frequency	~1.2 million cases annually worldwide

meningococcal disease is a life-threatening infection caused by the bacterium Neisseria meningitidis. It most commonly presents as meningitis, an inflammation of the protective membranes covering the brain and spinal cord, or as a devastating bloodstream infection known as meningococcemia. The disease progresses with alarming speed and carries a significant risk of death and long-term disability even with prompt medical treatment.

Signs and symptoms

Initial symptoms are often non-specific and can resemble those of influenza, including sudden onset of fever, intense headache, nausea, and vomiting. The classic triad for bacterial meningitis is fever, headache, and neck stiffness. A distinctive petechial rash that does not fade under pressure is a critical sign of meningococcemia and can rapidly evolve into purpura fulminans. Patients may exhibit photophobia, altered mental status, and in severe cases, progress to septic shock, multi-organ failure, and disseminated intravascular coagulation. Complications in survivors can include neurological deficits, sensorineural hearing loss, skin necrosis, and limb amputation due to gangrene.

Causes

The disease is caused exclusively by the Gram-negative diplococcus Neisseria meningitidis, also known as the meningococcus. At least 12 serogroups have been identified, with groups A, B, C, W, X, and Y being responsible for most invasive disease worldwide. The bacteria are transmitted through respiratory droplets and secretions from the nasopharynx of asymptomatic carriers or infected individuals. Close and prolonged contact, such as in household settings, military barracks, or college dormitories, facilitates transmission.

Pathophysiology

Neisseria meningitidis colonizes the nasopharyngeal mucosa, where it can evade the host immune system through mechanisms like capsular polysaccharide production and antigenic variation. In a small percentage of individuals, the bacteria invade the epithelium and enter the bloodstream, causing meningococcemia. Survival in the blood is mediated by the polysaccharide capsule, which confers resistance to complement-mediated lysis and phagocytosis. The bacteria can then cross the blood-brain barrier, likely via transcytosis through microvascular endothelial cells, to infect the cerebrospinal fluid and cause meningitis. Lipooligosaccharide (endotoxin) release triggers a massive systemic inflammatory response syndrome, leading to vascular damage, hypotension, and coagulopathy.

Diagnosis

Definitive diagnosis requires isolation of Neisseria meningitidis from a normally sterile site. Lumbar puncture for CSF analysis is crucial for suspected meningitis; findings typically show elevated white blood cells, low glucose, and high protein. Gram stain of CSF may demonstrate the characteristic Gram-negative diplococci. Blood culture and culture of petechial lesions are also essential. Rapid diagnostic tests include polymerase chain reaction assays on CSF or blood, which can detect bacterial DNA even after antibiotic administration. Identification of the specific serogroup is important for public health management and epidemiology.

Prevention

Primary prevention is achieved through vaccination. Several conjugate vaccines are available, such as those targeting serogroups A, C, W, and Y. Vaccines against serogroup B use different technologies, like the MenB-4C and MenB-FHbp vaccines. The World Health Organization recommends incorporation into national immunization schedules, especially in the African meningitis belt. For close contacts of a case, antibiotic prophylaxis with ciprofloxacin, ceftriaxone, or rifampin is recommended to eliminate carriage. General measures include avoiding crowding and promoting respiratory hygiene.

Treatment

Suspected cases constitute a medical emergency and require immediate administration of parenteral antibiotics before confirmatory test results. The gold standard is an intravenous third-generation cephalosporin such as ceftriaxone or cefotaxime. Penicillin G remains effective for susceptible strains but resistance is monitored. Adjunctive therapy is critical and includes aggressive fluid resuscitation, vasopressor support for septic shock, and management of intracranial pressure. The use of corticosteroids, like dexamethasone, is controversial but may be considered in certain settings to reduce neurological sequelae.

Epidemiology

Neisseria meningitidis causes an estimated 1.2 million cases and over 100,000 deaths annually worldwide. Incidence varies greatly by region and serogroup. The African meningitis belt, stretching from Senegal to Ethiopia, experiences high rates of seasonal epidemics, historically dominated by serogroup A but now seeing a rise of serogroup C, W, and X. In Europe, North America, and Australia, serogroups B, C, W, and Y are most common. Outbreaks frequently occur in closed communities like universities, hajj pilgrims, and military recruits. The highest burden of disease is in infants, with a secondary peak in adolescents and young adults.

Category:Infectious diseases Category:Bacterial diseases Category:Medical emergencies